BTIG Maintains a Hold Rating on Insulet (PODD)


BTIG analyst Marie Thibault maintained a Hold rating on Insulet (PODD) today. The company’s shares closed last Thursday at $215.15, close to its 52-week high of $219.86.

According to TipRanks.com, Thibault is a 4-star analyst with an average return of 12.8% and a 50.0% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Edwards Lifesciences.

Insulet has an analyst consensus of Moderate Buy, with a price target consensus of $200.42, which is a -4.6% downside from current levels. In a report issued on April 24, Leerink Partners also downgraded the stock to Hold.

See today’s analyst top recommended stocks >>

Insulet’s market cap is currently $13.57B and has a P/E ratio of 1147.60. The company has a Price to Book ratio of 568.79.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts